MIT and USDA's Chief Scientific Research Agency, Agricultural Research Service, Enter Collaborative Agreement to Evaluate the MIT 1000 System for Rapid Identification of Various Microbes

SAN CLEMENTE, CA--(Marketwire - June 23, 2008) - Micro Imaging Technology, Inc. (OTCBB: MMTC) announces that it has entered into a collaborative Material Transfer Agreement with Agricultural Research Services (ARS) to evaluate the MIT 1000 System for rapid identification of several bacterial pathogens. The MIT 1000 System currently has the ability to identify up to 23 species of bacteria in a matter of minutes at a cost of about 10 cents per test.

ARS is the chief scientific research agency of the U.S. Department of Agriculture. The evaluations will be conducted at ARS' Eastern Regional Research Center (ERRC) at Wyndmoor, Pennsylvania. ARS conducts research to develop and transfer solutions to agricultural problems of high national priority and provide information access and dissemination to: Ensure high-quality, safe food, and other agricultural products, assess the nutritional needs of Americans, sustain a competitive agricultural economy, enhance the natural resource base and the environment, and provide economic opportunities for rural citizens, communities, and society as a whole.

Under the terms of the Agreement, MIT provided an MIT 1000 System to ERRC where ARS scientists are initially evaluating the System's performance for the identification of Listeria monocytogenes and Staphylococcus aureus (S.aureus).

Listeria monocytogenes is a bacterium commonly found in soil, stream water, sewage, plants, and food. Listeria is known to be the bacteria responsible for listeriosis, a rare but lethal food-borne infection that has a devastating mortality rate of 25%.

S. aureus is a spherical bacterium, frequently living in an individual's nasal cavity that can cause a range of illnesses from minor skin infections, (e.g. pimples) to life-threatening diseases, such as pneumonia and meningitis. Some strains of S. aureus are resistant to antibiotics such as methicillin and penicillin. These strains are known as MRSA (Methicillin Resistant S. aureus). In November 2007, the Center for Disease Control reported that in 2005 over 278,000 people were diagnosed and hospitalized for MRSA-related infections and incidents are increasing at a rate from 6% to over 9% annually throughout the four major regions of the United States.

Several species and strains of both Listeria and Staphylococcus will be evaluated to determine the System's ability to repeatedly identify these organisms and the two organizations will then jointly address targeted applications that could inevitably prevent contaminated food from ever reaching the consumer. The Agreement is planned to be expanded to include the identification of Vibrio parahaemolyticus (a bacterium found in seafood), E.coli and Salmonella with the same overall objective.

Upon completion of the evaluation, a summary of the results will be made available to the public.

About Micro Imaging Technology

The Company has developed and patented a technology for rapid microbe detection and identification. This System measures scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. The MIT System is non-biological and does not rely on biological agents, conventional chemical processing, fluorescent tags, gas chromatography or DNA analysis.

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT recently performed over 300 tests for the identification the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report, in the Company's opinion, demonstrated the accuracy, speed and efficiency of the MIT System over conventional processes and is available from the Company.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

Contact Information: CONTACT: Michael Brennan Chairman Email: Telephone: (805) 557-0614